1 / 14

Chronic Obstructive Pulmonary Disease (copd) Treatment Market Analysis| Coherent Market Insights

The Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market was leading by US$ 14,209.0 Mn in 2017.

shrutiCMI
Télécharger la présentation

Chronic Obstructive Pulmonary Disease (copd) Treatment Market Analysis| Coherent Market Insights

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Coherent Market Insights Market Research and Business Consulting Services https://www.coherentmarketinsights.com/ COVID-19 Impact Tracker

  2. CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT MARKET ANALYSIS Chronic Obstructive Pulmonary Disease (COPD) Treatment Market by Drug Class (Bronchodilators (Beta 2-Agonists, Anticholinergics, Theophyllines), Phosphodiesterase Type 4 Inhibitors, Steroids, and Others), By Route of Administration (Oral and Inhalation), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa) - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2019 – 2026

  3. Market Insights Chronic obstructive pulmonary disease (COPD) involves lung inflammation, causing obstruction of airflow from the lungs. It is a chronic disease and symptoms include difficulty in breathing, mucus formation, wheezing, and others. COPD is a progressive lung disease, which includes chronic bronchitis, emphysema, and refractory asthma. Prime causes behind occurrence of chronic obstructive pulmonary disease include smoking, air pollution, secondhand smoke, alpha-1 deficiency-related emphysema (rare form of COPD), and others. There are certain ways, by which complications can be prevented, as well as disease progression can be slowed down. These may include quitting smoking, adherence to the prescribed medication, and preventing associated co-morbidities such as flu, pneumonia, and others by vaccination against these diseases.

  4. Figure 1. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), by Region, 2018 & 2026

  5. Market Growth According to National Center for Biotechnology Information (NCBI), in 2016, chronic obstructive pulmonary disease (COPD) was the third leading cause of death, globally. Furthermore, according Global Burden of Disease Study, COPD was prevalent in over 300 million people globally in 2013. Moreover, according to the same source, in European adults over 40 years of age, the prevalence of COPD ranged from 15-20%, in 2016. Moreover, according to the World Health Organization (WHO), Global Burden of Disease Study reports prevalence of 251 million cases of COPD, globally, in 2016. Increasing prevalence is expected to support the global chronic obstructive pulmonary disease (COPD) treatment market growth over the forecast period. Organizations such as World Health Organization (WHO), COPD Foundation, American Thoracic Society, and Centers for Disease Control and Prevention (CDC) work towards raising COPD awareness in the population. National Institutes of Health (NIH) runs an initiative, ‘COPD Learn More Breathe Better’, and celebrates November as a national COPD awareness month. These factors are expected to support global chronic obstructive pulmonary disease (COPD) treatment market growth over the forecast period.

  6. The global chronic obstructive pulmonary disease (COPD) treatment market size was valued at US$ 14,209.0 million in 2017, and is expected to witness a robust CAGR of 4.9% over the forecast period (2018–2026).

  7. Research and Development • Verona Pharma commenced a phase IIb clinical trial to assess nebulized ensifentrine (RPL554),in combination with a long-acting bronchodilator to treat moderate to severe COPD,inMay 2019.Novartis AG launched UltibroBreezhaler and SeebriBreezhaler in China for the treatment of COPD,inMarch 2019. Cipla launched Niveoli,beclomethasone-formoterolcombination hydrofluoroalkane(HFA) inhaler for adults suffering from obstructive airway diseases(OAD) such as asthma and COPD,inApril 2019.Moreover,manufacturers are also involved in improving overall COPD treatment paradigm by introducing medical devices,web-based applications, and other efforts to reduce the global burden of chronic obstructive pulmonary disease.

  8. For instance,Spire Health launched a study to develop new digital biomarkers that can predict exacerbations—and potentially hospitalizations—in patients with severe COPD,in May 2019.These factors are expected to support global chronic obstructive pulmonary disease (COPD) treatment market growth over the forecast period. • However, development of new drugs is a challenging task and drug failures in clinical trials have affected growth of the market. For instance, asthma drug benralizumab failed to decrease annual COPD exacerbation rates for patients with moderate to very severe COPD, in May 2019. The Phase III, randomized, double-blind, placebo-controlled, parallel-group clinical trials GALATHEA and TERRANOVA evaluated the efficacy and safety of benralizumab for the prevention of exacerbations in patients with moderate to very severe COPD.

  9. Figure 2.Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share,byDistribution Channel, 2018 & 2026

  10. Competitive Section Some major players operating in the global chronic obstructive pulmonary disease (COPD) treatment market include AstraZeneca Plc, Orion Corporation, Mylan N.V., BoehringerIngelheim, Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc, Novartis AG, Sunovion Pharmaceuticals, Inc., and CHIESI FarmaceuticiSpA

  11. Request Sample Report • Request Customization • Download PDF Brochure • Talk to Analyst Reference: https://www.coherentmarketinsights.com/market-insight/chronic-obstructive-pulmonary-disease-copd-treatment-market-2656

  12. About Us Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. What we provide: • Customized Market Research Services • Industry Analysis Services • Business Consulting Services • Market Intelligence Services • Long term Engagement Model • Country Specific Analysis

  13. Contact Us Mr. Shah Coherent Market Insights Pvt.Ltd. Address: 1001 4th Ave, #3200 Seattle, WA 98154, U.S. Phone: +1-206-701-6702 Email: sales@coherentmarketinsights.com

  14. Thank You! Kindly follow CMI Social Media Profiles for the latest company updates Facebook Linkedin Twitter https://www.coherentmarketinsights.com/

More Related